Table 2.
Laboratory findings of the four patients with COVID‐19
| Laboratory findings | Normal range | NPPP (n = 2) | PPP (n = 2) | t | P |
|---|---|---|---|---|---|
| mean ± SD | mean ± SD | ||||
| WBC, ×109/L | 3.5‐9.5 | 3.95 ± 0.48 | 7.95 ± 2.72 | −1.660 | .334 |
| N, ×109/L | 1.8‐6.3 | 1.83 ± 0.53 | 4.39 ± 1.35 | −2.479 | .195 |
| L, ×109/L | 1.1‐3.2 | 1.56 ± 1.12 | 2.11 ± 1.16 | −0.480 | .679 |
| NE% | 50‐70 | 47.60 ± 19.23 | 61.90 ± 4.52 | −1.024 | .479 |
| LC% | 20‐40 | 38.25 ± 23.97 | 28.35 ± 5.44 | 0.570 | .663 |
| Hb, g/L | 120‐172 | 142.00 ± 0.00 | 152.50 ± 2.12 | −7.000 | .090 |
| PLT, ×109/L | 125‐350 | 215.50 ± 58.68 | 214.50 ± 28.99 | 0.022 | .985 |
| LA, mmol/L | 0.4‐2.0 | 2.04 ± 1.27 | 1.70 ± 0.84 | 0.311 | .789 |
| ALT, U/L | 7‐40 (F) 9‐50 (M) | 40.00 ± 28.28 | 59.00 ± 5.65 | −0.932 | .513 |
| AST, U/L | 13‐35 (F) 15‐40 (M) | 62.50 ± 21.41 | 51.50 ± 4.94 | 0.217 | .864 |
| T‐Bil, μmol/L | 3.4‐20.5 | 13.10 ± 2.54 | 15.10 ± 1.69 | −0.925 | .465 |
| D‐Bil, μmol/L | 1‐20.1 | 2.95 ± 0.35 | 3.05 ± 0.49 | −0.232 | .840 |
| ALB, g/L | 40‐55 | 35.70 ± 1.41 | 44.95 ± 1.06 | −7.400 | .022 |
| PT, S | 9.9‐12.8 | 13.00 ± 0.28 | 11.85 ± 0.35 | 3.592 | .074 |
| Crea, μmol/L | 41‐81 | 53.50 ± 3.53 | 86.50 ± 4.94 | −7.672 | .022 |
| CK‐MB, ng/mL | <3.6 | 0.20 ± 0.05 | 0.61 ± 0.09 | −5.438 | .047 |
| TNI, ng/mL | <0.056 | 0.01 ± 0.01 | 0.01 ± 0.00 | 0.400 | .758 |
| SPO2(FIO2 = 21%) | >90% | 98.00 ± 0.00 | 97.00 ± 1.41 | 1.000 | .500 |
Note: N is the total number of patients with available data.
Abbreviations: ALB, album; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK‐MB, creatine kinase‐MB; COVID‐19, coronavirus disease 2019; F, female; Hb, hemoglobin; LA, lactic acid; LC, lymphocyte percentage; M, male; NE, neutrophil; NPPP, non‐persistently PCR positive; PCR, polymerase chain reaction; PLT, platelat; PPP, persistently PCR positive; PT, prothrombin time; TNI, Troponin I; WBC, white blood cell.